Loading…
EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
Saved in:
| Published in: | Hematological oncology 2023-06, Vol.41 (S2), p.125-127 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c1434-7a01e58966868d1bc49cd7cd3fd1f436300bc5f953b7b0e980540b33687b9d863 |
|---|---|
| cites | |
| container_end_page | 127 |
| container_issue | S2 |
| container_start_page | 125 |
| container_title | Hematological oncology |
| container_volume | 41 |
| creator | Belada, D. Falchi, L. Leppä, S. Vermaat, J. S. Holte, H. Hutchings, M. Lugtenburg, P. de Vos, S. Abrisqueta, P. Nijland, M. Merryman, R. W. Christensen, J. H. Wahlin, B. E. Linton, K. M. Wang, L. Abbas, A. Rana, A. Quadri, S. Sureda, A. |
| description | |
| doi_str_mv | 10.1002/hon.3163_84 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3089983258</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089983258</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1434-7a01e58966868d1bc49cd7cd3fd1f436300bc5f953b7b0e980540b33687b9d863</originalsourceid><addsrcrecordid>eNotkMtOwzAQRS0EEqWw4gcssQGVlHGch710m7SxcOsoDx6rqHkJKmhLQhfsWLLkG_kSUrWr0Zl7NCNdhC4JDAmAefeyXg0pcWjGrCPUI8C5QcDhx6gHpssMMKl5is7adgnQZcB66McPxzqSiZiJEX6USYA7SJ_kDgdY-XOhpKdn0vPxdWTe4DDSDx3E2EsjMVI-jvw41PO428g5DuQ0-Pv-jWR8jydaKTlOlYiwep6FgZ6J286eishTfhxjPcGh9kwLx4lI0vgcndSLt7a6OMw-Sid-Mg4MpadyLJRREItahrsAUtmMOw5zWEnywuJF6RYlrUtSW9ShAHlh19ymuZtDxRnYFuSUOszNeckc2kdX-7ubZv2xrdrPbLneNqvuZUaBcc6oabPOGuytolm3bVPV2aZ5fV80XxmBbFd11lWdHaqm_4y6Zl0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089983258</pqid></control><display><type>article</type><title>EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Belada, D. ; Falchi, L. ; Leppä, S. ; Vermaat, J. S. ; Holte, H. ; Hutchings, M. ; Lugtenburg, P. ; de Vos, S. ; Abrisqueta, P. ; Nijland, M. ; Merryman, R. W. ; Christensen, J. H. ; Wahlin, B. E. ; Linton, K. M. ; Wang, L. ; Abbas, A. ; Rana, A. ; Quadri, S. ; Sureda, A.</creator><creatorcontrib>Belada, D. ; Falchi, L. ; Leppä, S. ; Vermaat, J. S. ; Holte, H. ; Hutchings, M. ; Lugtenburg, P. ; de Vos, S. ; Abrisqueta, P. ; Nijland, M. ; Merryman, R. W. ; Christensen, J. H. ; Wahlin, B. E. ; Linton, K. M. ; Wang, L. ; Abbas, A. ; Rana, A. ; Quadri, S. ; Sureda, A.</creatorcontrib><identifier>ISSN: 0278-0232</identifier><identifier>EISSN: 1099-1069</identifier><identifier>DOI: 10.1002/hon.3163_84</identifier><language>eng</language><publisher>Chichester: Wiley Subscription Services, Inc</publisher><subject>Lymphoma ; Rituximab</subject><ispartof>Hematological oncology, 2023-06, Vol.41 (S2), p.125-127</ispartof><rights>2023 The Authors. Hematological Oncology published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1434-7a01e58966868d1bc49cd7cd3fd1f436300bc5f953b7b0e980540b33687b9d863</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Belada, D.</creatorcontrib><creatorcontrib>Falchi, L.</creatorcontrib><creatorcontrib>Leppä, S.</creatorcontrib><creatorcontrib>Vermaat, J. S.</creatorcontrib><creatorcontrib>Holte, H.</creatorcontrib><creatorcontrib>Hutchings, M.</creatorcontrib><creatorcontrib>Lugtenburg, P.</creatorcontrib><creatorcontrib>de Vos, S.</creatorcontrib><creatorcontrib>Abrisqueta, P.</creatorcontrib><creatorcontrib>Nijland, M.</creatorcontrib><creatorcontrib>Merryman, R. W.</creatorcontrib><creatorcontrib>Christensen, J. H.</creatorcontrib><creatorcontrib>Wahlin, B. E.</creatorcontrib><creatorcontrib>Linton, K. M.</creatorcontrib><creatorcontrib>Wang, L.</creatorcontrib><creatorcontrib>Abbas, A.</creatorcontrib><creatorcontrib>Rana, A.</creatorcontrib><creatorcontrib>Quadri, S.</creatorcontrib><creatorcontrib>Sureda, A.</creatorcontrib><title>EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS</title><title>Hematological oncology</title><subject>Lymphoma</subject><subject>Rituximab</subject><issn>0278-0232</issn><issn>1099-1069</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkMtOwzAQRS0EEqWw4gcssQGVlHGch710m7SxcOsoDx6rqHkJKmhLQhfsWLLkG_kSUrWr0Zl7NCNdhC4JDAmAefeyXg0pcWjGrCPUI8C5QcDhx6gHpssMMKl5is7adgnQZcB66McPxzqSiZiJEX6USYA7SJ_kDgdY-XOhpKdn0vPxdWTe4DDSDx3E2EsjMVI-jvw41PO428g5DuQ0-Pv-jWR8jydaKTlOlYiwep6FgZ6J286eishTfhxjPcGh9kwLx4lI0vgcndSLt7a6OMw-Sid-Mg4MpadyLJRREItahrsAUtmMOw5zWEnywuJF6RYlrUtSW9ShAHlh19ymuZtDxRnYFuSUOszNeckc2kdX-7ubZv2xrdrPbLneNqvuZUaBcc6oabPOGuytolm3bVPV2aZ5fV80XxmBbFd11lWdHaqm_4y6Zl0</recordid><startdate>202306</startdate><enddate>202306</enddate><creator>Belada, D.</creator><creator>Falchi, L.</creator><creator>Leppä, S.</creator><creator>Vermaat, J. S.</creator><creator>Holte, H.</creator><creator>Hutchings, M.</creator><creator>Lugtenburg, P.</creator><creator>de Vos, S.</creator><creator>Abrisqueta, P.</creator><creator>Nijland, M.</creator><creator>Merryman, R. W.</creator><creator>Christensen, J. H.</creator><creator>Wahlin, B. E.</creator><creator>Linton, K. M.</creator><creator>Wang, L.</creator><creator>Abbas, A.</creator><creator>Rana, A.</creator><creator>Quadri, S.</creator><creator>Sureda, A.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>202306</creationdate><title>EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS</title><author>Belada, D. ; Falchi, L. ; Leppä, S. ; Vermaat, J. S. ; Holte, H. ; Hutchings, M. ; Lugtenburg, P. ; de Vos, S. ; Abrisqueta, P. ; Nijland, M. ; Merryman, R. W. ; Christensen, J. H. ; Wahlin, B. E. ; Linton, K. M. ; Wang, L. ; Abbas, A. ; Rana, A. ; Quadri, S. ; Sureda, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1434-7a01e58966868d1bc49cd7cd3fd1f436300bc5f953b7b0e980540b33687b9d863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Lymphoma</topic><topic>Rituximab</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Belada, D.</creatorcontrib><creatorcontrib>Falchi, L.</creatorcontrib><creatorcontrib>Leppä, S.</creatorcontrib><creatorcontrib>Vermaat, J. S.</creatorcontrib><creatorcontrib>Holte, H.</creatorcontrib><creatorcontrib>Hutchings, M.</creatorcontrib><creatorcontrib>Lugtenburg, P.</creatorcontrib><creatorcontrib>de Vos, S.</creatorcontrib><creatorcontrib>Abrisqueta, P.</creatorcontrib><creatorcontrib>Nijland, M.</creatorcontrib><creatorcontrib>Merryman, R. W.</creatorcontrib><creatorcontrib>Christensen, J. H.</creatorcontrib><creatorcontrib>Wahlin, B. E.</creatorcontrib><creatorcontrib>Linton, K. M.</creatorcontrib><creatorcontrib>Wang, L.</creatorcontrib><creatorcontrib>Abbas, A.</creatorcontrib><creatorcontrib>Rana, A.</creatorcontrib><creatorcontrib>Quadri, S.</creatorcontrib><creatorcontrib>Sureda, A.</creatorcontrib><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Hematological oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Belada, D.</au><au>Falchi, L.</au><au>Leppä, S.</au><au>Vermaat, J. S.</au><au>Holte, H.</au><au>Hutchings, M.</au><au>Lugtenburg, P.</au><au>de Vos, S.</au><au>Abrisqueta, P.</au><au>Nijland, M.</au><au>Merryman, R. W.</au><au>Christensen, J. H.</au><au>Wahlin, B. E.</au><au>Linton, K. M.</au><au>Wang, L.</au><au>Abbas, A.</au><au>Rana, A.</au><au>Quadri, S.</au><au>Sureda, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS</atitle><jtitle>Hematological oncology</jtitle><date>2023-06</date><risdate>2023</risdate><volume>41</volume><issue>S2</issue><spage>125</spage><epage>127</epage><pages>125-127</pages><issn>0278-0232</issn><eissn>1099-1069</eissn><cop>Chichester</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1002/hon.3163_84</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0278-0232 |
| ispartof | Hematological oncology, 2023-06, Vol.41 (S2), p.125-127 |
| issn | 0278-0232 1099-1069 |
| language | eng |
| recordid | cdi_proquest_journals_3089983258 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Lymphoma Rituximab |
| title | EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A39%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EPCORITAMAB%20WITH%20RITUXIMAB%20+%20LENALIDOMIDE%20(R2)%20PROVIDES%20DURABLE%20RESPONSES%20IN%20HIGH%E2%80%90RISK%20FOLLICULAR%20LYMPHOMA,%20REGARDLESS%20OF%20POD24%20STATUS&rft.jtitle=Hematological%20oncology&rft.au=Belada,%20D.&rft.date=2023-06&rft.volume=41&rft.issue=S2&rft.spage=125&rft.epage=127&rft.pages=125-127&rft.issn=0278-0232&rft.eissn=1099-1069&rft_id=info:doi/10.1002/hon.3163_84&rft_dat=%3Cproquest_cross%3E3089983258%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1434-7a01e58966868d1bc49cd7cd3fd1f436300bc5f953b7b0e980540b33687b9d863%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3089983258&rft_id=info:pmid/&rfr_iscdi=true |